+

WO2003010184A3 - Motif conserve d'interaction de xiap dans la caspase-9 et la proteine smac/diablo pour moduler l'apoptose - Google Patents

Motif conserve d'interaction de xiap dans la caspase-9 et la proteine smac/diablo pour moduler l'apoptose Download PDF

Info

Publication number
WO2003010184A3
WO2003010184A3 PCT/US2002/003553 US0203553W WO03010184A3 WO 2003010184 A3 WO2003010184 A3 WO 2003010184A3 US 0203553 W US0203553 W US 0203553W WO 03010184 A3 WO03010184 A3 WO 03010184A3
Authority
WO
WIPO (PCT)
Prior art keywords
caspase
diablo
xiap
smac
conserved
Prior art date
Application number
PCT/US2002/003553
Other languages
English (en)
Other versions
WO2003010184A2 (fr
Inventor
Emad S Alnemri
Original Assignee
Univ Jefferson
Emad S Alnemri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson, Emad S Alnemri filed Critical Univ Jefferson
Priority to AU2002253908A priority Critical patent/AU2002253908A1/en
Priority to IL15716802A priority patent/IL157168A0/xx
Publication of WO2003010184A2 publication Critical patent/WO2003010184A2/fr
Publication of WO2003010184A3 publication Critical patent/WO2003010184A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des peptides et des polypeptides associés à la caspase-9 et capables de se fixer à un inhibiteur de protéine d'apoptose (IAP), ainsi qu'un mutant de caspase-9, qui ne subissent pas de traitement normal et ne se fixent pas à une IAP. L'invention concerne en outre des molécules d'acide nucléique, notamment des vecteurs d'expression, qui codent lesdits peptides et polypeptides. Lesdits peptides et polypeptides sont utilisés pour provoquer l'apoptose et identifier des inhibiteurs et des amplificateurs d'apoptose.
PCT/US2002/003553 2001-02-08 2002-02-06 Motif conserve d'interaction de xiap dans la caspase-9 et la proteine smac/diablo pour moduler l'apoptose WO2003010184A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002253908A AU2002253908A1 (en) 2001-02-08 2002-02-06 A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
IL15716802A IL157168A0 (en) 2001-04-12 2002-03-28 Method and apparatus for measuring the position, shape, size and intensity distribution of the effective focal spot of an x-ray tube

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26796601P 2001-02-08 2001-02-08
US60/267,966 2001-02-08

Publications (2)

Publication Number Publication Date
WO2003010184A2 WO2003010184A2 (fr) 2003-02-06
WO2003010184A3 true WO2003010184A3 (fr) 2003-08-14

Family

ID=23020873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003553 WO2003010184A2 (fr) 2001-02-08 2002-02-06 Motif conserve d'interaction de xiap dans la caspase-9 et la proteine smac/diablo pour moduler l'apoptose

Country Status (2)

Country Link
AU (1) AU2002253908A1 (fr)
WO (1) WO2003010184A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005218555B2 (en) 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
JP5122275B2 (ja) 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
BRPI0511350A (pt) 2004-07-02 2007-12-04 Genentech Inc composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
AU2005319305B2 (en) 2004-12-20 2012-08-23 Genentech, Inc. Pyrrolidine inhibitors of IAP
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
KR20090094461A (ko) 2006-12-19 2009-09-07 제넨테크, 인크. Ｉａｐ의 이미다조피리딘 억제제
RU2491276C2 (ru) 2007-04-30 2013-08-27 Дженентек, Инк. Ингибиторы iap
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE PIR [online] 16 July 1999 (1999-07-16), AHRENS C.A. ET AL., XP002962285, Database accession no. (T10375) *
KIPP R.A. ET AL.: "Molecular targeting of inhibitor of apoptosis based on small molecule mimics of natural binding partners", BIOCHEM., vol. 41, 2002, pages 7344 - 7349, XP002962287 *
LIU Z. ET AL.: "Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain", NATURE, vol. 408, no. 21, 28 December 2000 (2000-12-28), pages 1004 - 1008, XP002909550 *
SRINIVASULA S.M. ET AL.: "A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis", NATURE, vol. 410, 1 March 2001 (2001-03-01), pages 112 - 116, XP002962286 *
VIROLOGY, vol. 229, 1997, pages 381 - 399 *
WRIGHT C.W. ET AL.: "Sequence requirements of Hid binding and apoptosis regulation in the Baculovirus inhibitor of apoptosis OP-IAP", J. BIOL. CHEM., vol. 277, no. 4, 25 January 2002 (2002-01-25), pages 2454 - 2462, XP002962288 *

Also Published As

Publication number Publication date
WO2003010184A2 (fr) 2003-02-06
AU2002253908A1 (en) 2003-02-17

Similar Documents

Publication Publication Date Title
AU2003249920A1 (en) Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO1999058571A3 (fr) Proteine hybride pour l'inhibition de la degranulation des mastocytes et son utilisation
WO1997033996A3 (fr) Bikunine humaine
EP2267018A3 (fr) Polypeptides de liaison pour la protéine stimulatrice des lymphocytes B (BLyS)
WO2002016418A3 (fr) Peptide ou polypeptide capable de liaison avec l'inhibiteur de la proteine de l'apoptose
WO2004061080A3 (fr) Polypeptides lies au stress et utilisation desdits polypeptides
WO2003010184A3 (fr) Motif conserve d'interaction de xiap dans la caspase-9 et la proteine smac/diablo pour moduler l'apoptose
WO2003057708A3 (fr) Proteines de fusion
WO2002040683A3 (fr) Proteines kinase humaines isolees, molecules d'acides nucleiques codant pour des proteines kinase humaines et utilisations
WO2002046407A3 (fr) Proteines transporteuses humaines isolees, molecules d'acides nucleiques codant pour les proteines transporteuses humaines et utilisation de ces dernieres
WO2006126198A3 (fr) Fragments de terminus c de molecule arts t mimetiques
WO2003060067A3 (fr) Acides nucleiques et polypeptides p85-alpha, et procedes associes
WO2003087145A3 (fr) Nouveaux polypeptides purifies impliques dans la detection de densite cellulaire
AU2003902414A0 (en) Flowering induction
WO2004022587A3 (fr) Paire de polypeptides a interaction forte et specifique
WO2002070699A3 (fr) Nouveaux cofacteurs du recepteur alpha des oestrogenes et procedes d'utilisation
WO2001081412A3 (fr) Proteines de transport humaines isolees, molecules d'acides nucleiques codant pour ces proteines de transport humaines et utilisations de ces proteines
WO2002046406A3 (fr) Proteines transporteurs humaines isolees, molecules d'acides nucleiques codant ces proteines, et utilisations correspondantes
WO2003074675A3 (fr) Proteines de type ras humaines isolees, molecules d'acide nucleique codant ces proteines de type ras humaines et leurs utilisations
WO2002024910A3 (fr) Proteines transporteuses humaines isolees, molecules d'acides nucleiques codant pour ces proteines transporteuses humaines et utilisations
WO2002057310A3 (fr) Proteines de transport humaines isolees, molecules d'acide nucleique codant des proteines de transport humaines et utilisations associees
WO2002072765A3 (fr) Proteines de type ras humaines isolees, molecule d'acides nucleiques codant pour ces proteines de type ras, et leurs utilisations
WO2002022824A3 (fr) Genes de ashbya gossypii codant pour des proteines participant au transport membranaire
WO2002046217A3 (fr) Proteines humaines de transport isolees, molecules d'acide nucleique codant pour ces proteines humaines de transport et utilisations desdites proteines
WO2002020757A3 (fr) Proteines transporteuses humaines isolees, molecules d'acides nucleiques codant pour lesdites molecules transporteuses humaines et utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载